Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Opthea stock | $9.15

Learn how to easily invest in Opthea stock.

Opthea Limited
-$0.95 (-12.62%)

Opthea Limited is a biotechnology business based in the US. Opthea shares (OPT) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Opthea

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – OPT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Opthea stock price (NASDAQ: OPT)

Use our graph to track the performance of OPT stocks over time.

Opthea shares at a glance

Information last updated 2021-07-28.
Latest market close$9.15
52-week range$7.09 - $18.06
50-day moving average $8.02
200-day moving average $9.49
Wall St. target price$36.54
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Opthea shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Opthea stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Opthea price performance over time

Historical closes compared with the close of $9.15 from 2021-05-28

1 week (2021-07-22) N/A
1 month (2021-07-02) 20.71%
3 months (2021-04-30) -0.87%
6 months (2021-01-29) N/A
1 year (2020-07-29) N/A
2 years (2019-07-29) N/A
3 years (2018-07-29) N/A
5 years (2016-07-29) N/A

Opthea financials

Revenue TTM $228,254
Gross profit TTM $-393,700
Return on assets TTM -16.98%
Return on equity TTM -32.37%
Profit margin 0%
Book value $4.68
Market capitalisation $327.1 million

TTM: trailing 12 months

Shorting Opthea shares

There are currently 151,322 Opthea shares held short by investors – that's known as Opthea's "short interest". This figure is 0.3% down from 151,803 last month.

There are a few different ways that this level of interest in shorting Opthea shares can be evaluated.

Opthea's "short interest ratio" (SIR)

Opthea's "short interest ratio" (SIR) is the quantity of Opthea shares currently shorted divided by the average quantity of Opthea shares traded daily (recently around 302644). Opthea's SIR currently stands at 0.5. In other words for every 100,000 Opthea shares traded daily on the market, roughly 500 shares are currently held short.

To gain some more context, you can compare Opthea's short interest ratio against those of similar companies.

However Opthea's short interest can also be evaluated against the total number of Opthea shares, or, against the total number of tradable Opthea shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Opthea's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Opthea shares in existence, roughly 0 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable Opthea shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Opthea.

Find out more about how you can short Opthea stock.

Opthea share dividends

We're not expecting Opthea to pay a dividend over the next 12 months.

Opthea share price volatility

Over the last 12 months, Opthea's shares have ranged in value from as little as $7.09 up to $18.0624. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Opthea's is -0.0454. This would suggest that Opthea's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Opthea has bucked the trend.

To put Opthea's beta into context you can compare it against those of similar companies.

Opthea overview

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia. .

Frequently asked questions

What percentage of Opthea is owned by institutions?
Currently 21.19% of Opthea shares are held by institutions.
When does the fiscal year end for Opthea?
Opthea's fiscal year ends in June.
Where is Opthea based?
Opthea's address is: 650 Chapel Street, South Yarra, VIC, Australia, 3141

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site